D.E. Shaw & Co
DYN icon

D.E. Shaw & Co’s Dyne Therapeutics DYN Stock Holding History

D.E. Shaw & Co’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$1.42M – 4553
2024
Q1 		$1.42M Buy
+50,000
New +$1.13M ﹤0.01% 2870

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

D.E. Shaw & Co's DYN Position: Q2 2026 in Review

D.E. Shaw & Co opened a new position in Dyne Therapeutics (DYN) in Q2 2026: 60,161 shares worth $1.34M. The stake represents ﹤0.01% of the portfolio and ranks #3543 among its holdings. This is a return to the name: D.E. Shaw & Co previously reported a position in DYN as recently as Q3 2025.

D.E. Shaw & Co first reported a position in DYN in Q4 2020 and has held it in 10 quarters since. The position peaked at $4.85M in Q2 2025. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • D.E. Shaw & Co held 60,161 shares of Dyne Therapeutics worth $1.34M as of Q2 2026.
  • Dyne Therapeutics was a new D.E. Shaw & Co position in Q2 2026.
  • Dyne Therapeutics made up ﹤0.01% of D.E. Shaw & Co's portfolio in Q2 2026, its #3543 holding.
  • D.E. Shaw & Co first reported a position in Dyne Therapeutics in Q4 2020 and has held it in 10 quarters since.
  • D.E. Shaw & Co's Dyne Therapeutics position peaked at $4.85M in Q2 2025.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on D.E. Shaw & Co's 13F filing for Q2 2026, filed 14 Aug 2026.